Search research articles
Contact Us
Filters
Showing results (81-90 of 138) with videos related to
Page
of 14
Sort By:
Medical Oncology (Northwood, London, England)
|
February 12, 2013
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials
José María del Campo, Cristiana Sessa, Carolyn N Krasner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 13, 2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group
Agop Y Bedikian, Michael Millward, Hubert Pehamberger, et al.
European Urology
|
July 23, 2014
Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers
Sakshi Gulati, Pierre Martinez, Tejal Joshi, et al.
Molecular Cancer Therapeutics
|
May 8, 2007
p53 therapy in a patient with Li-Fraumeni syndrome
Neil Senzer, John Nemunaitis, Michael Nemunaitis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2011
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
Jonathan A Ledermann, Allan Hackshaw, Stan Kaye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2008
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial
Alain Ravaud, Robert Hawkins, Jason P Gardner, et al.
Gynecologic Oncology
|
February 19, 2018
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer
Amit Oza, Stanley Kaye, Jan Van Tornout, et al.
Cancer Discovery
|
December 18, 2012
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma
Maria R Girotti, Malin Pedersen, Berta Sanchez-Laorden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2016
A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Robert E Hawkins, Martin Gore, Yaroslav Shparyk, et al.
Cancer Discovery
|
February 6, 2026
Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
Maria R Girotti, Malin Pedersen, Berta Sanchez-Laorden, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 138) with videos related to
Sort By:
Page
of 14
Medical Oncology (Northwood, London, England)
|
February 12, 2013
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials
José María del Campo, Cristiana Sessa, Carolyn N Krasner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 13, 2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group
Agop Y Bedikian, Michael Millward, Hubert Pehamberger, et al.
European Urology
|
July 23, 2014
Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers
Sakshi Gulati, Pierre Martinez, Tejal Joshi, et al.
Molecular Cancer Therapeutics
|
May 8, 2007
p53 therapy in a patient with Li-Fraumeni syndrome
Neil Senzer, John Nemunaitis, Michael Nemunaitis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2011
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
Jonathan A Ledermann, Allan Hackshaw, Stan Kaye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2008
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial
Alain Ravaud, Robert Hawkins, Jason P Gardner, et al.
Gynecologic Oncology
|
February 19, 2018
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer
Amit Oza, Stanley Kaye, Jan Van Tornout, et al.
Cancer Discovery
|
December 18, 2012
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma
Maria R Girotti, Malin Pedersen, Berta Sanchez-Laorden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2016
A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Robert E Hawkins, Martin Gore, Yaroslav Shparyk, et al.
Cancer Discovery
|
February 6, 2026
Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
Maria R Girotti, Malin Pedersen, Berta Sanchez-Laorden, et al.
Page
of 14